drugset / Trial / NCT06949059
Intravenous Hydromorphone for the Treatment of Acute Pain
Phase 1/2
Recruiting
30 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Yichang Humanwell Pharmaceutical Co., Ltd., China · collab
NaSingle-groupOpen-labelTreatment
Summary
To observe the efficacy and safety of hydromorphone in the treatment of acute chest pain, and to explore the potential advantages of hydromorphone for analgesia in patients with acute chest pain, so as to provide more theoretical basis for individualized analgesia and rapid recovery in patients with acute chest pain.
Timeline
- Start
- 2025-01-01
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydromorphone | Other / unclassified | 1 mg | Intravenous |